LIVN
LivaNova PLC · Healthcare
63.54
0.06%(+0.04)
Close70.98
11.71%(+7.44)
After HoursLast Updated: — ET
52W L: $32.4852W H: $71.92
$64.08
CHG+1.73 (+2.77%)
H$65.90
L$57.51
VOL14M
LIVN (1h)
LivaNova PLC · Healthcare
SG Americas Securities LLC raised its stake in shares of LivaNova PLC (NASDAQ: LIVN) by 83.9% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 24,257 shares of the company's stock after buying an additional 11,066 shares during the quarter. SG Americas
Allspring Global Investments Holdings LLC lessened its holdings in shares of LivaNova PLC (NASDAQ: LIVN) by 8.9% during the undefined quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 201,832 shares of the company's stock after selling 19,629 shares during the period. Allspring Global Investments Holdings LLC
Exchange Traded Concepts LLC purchased a new position in shares of LivaNova PLC (NASDAQ: LIVN) in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor purchased 15,768 shares of the company's stock, valued at approximately $970,000. A number of other
LIVN wins FDA nod for its aura6000 sleep apnea system, marking a pivotal step in neurostimulation with strong trial results and new growth potential.
LONDON--(BUSINESS WIRE)---- $LIVN #OSA--LivaNova PLC (Nasdaq: LIVN), a market-leading medical technology company, will host a conference call to discuss its first-quarter 2026 results on Wed., May 6, 2026, at 1 p.m. London time (8 a.m. Eastern Daylight Time). The Company will release its first-quarter 2026 results prior to the call. The audiocast will be accessible at www.livanova.com/events. Listeners should log on approximately 10 minutes in advance to ensure proper setup to receive the audiocast. To listen.
LivaNova PLC (NASDAQ: LIVN - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the ten ratings firms that are presently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to
Tezel Ahmet
officer: Chief Innovation Officer
13,873 SH @ $0.00
2026-03-30
Tezel Ahmet
officer: Chief Innovation Officer
3,408 SH @ $0.00
2026-03-30
Tezel Ahmet
officer: Chief Innovation Officer
3,408 SH @ $0.00
2026-03-30
Tezel Ahmet
officer: Chief Innovation Officer
4,624 SH @ $0.00
2026-03-30
Tezel Ahmet
officer: Chief Innovation Officer
1,186 SH @ $61.27
2026-03-30
Poletti Franco
officer: President, Cardiopulmonary
3,184 SH @ $0.00
2026-03-30
Poletti Franco
officer: President, Cardiopulmonary
1,370 SH @ $61.27
2026-03-30
Poletti Franco
officer: President, Cardiopulmonary
2,130 SH @ $0.00
2026-03-30